

1 Membranous Nephropathy in the UK Biobank

2

3 *Patrick Hamilton^{1,2,3}, *Kieran Blaikie^{1,4}, Stephen A. Roberts^{1,4}, Matthew Gittins^{1,4}, Mallory L. Downie⁵,
4 Sanjana Gupta⁵, Catalin Voinescu⁵, Durga Kanigicherla^{1,3}, Horia Stanescu⁵, Robert Kleta⁵, Paul Brenchley^{1,3}

5 1 Manchester Academic Health Science Centre (MAHSC), The University of Manchester, 46 Grafton
6 Street, Manchester, M13 9NT

7 2 Wellcome Centre for Cell-Matrix Research, Division of Cell Matrix Biology and Regenerative
8 Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of
9 Manchester, Oxford Road, M13 9PL

10 3 Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, Oxford
11 Road, Manchester, M13 9WL

12 4 Centre for Biostatistics, The University of Manchester, Oxford Road, M13 9PL

13 5 UCL Department of Renal Medicine, UCL Medical School, Rowland Hill Street, London, NW3 2PF

14

15

16 *Joint first author

17

18 Corresponding Author

19 Dr Patrick Hamilton

20 patrick.hamilton@manchester.ac.uk

21

22

23

24

25 Abstract

26 Background: Despite MN being one of the most common causes of nephrotic syndrome worldwide, its biological
27 and environmental determinants are poorly understood in large-part due to it being a rare disease. Making use
28 of the UK Biobank, a unique resource holding a clinical dataset and stored DNA, serum and urine for ~500,000
29 participants, this study aims to address this gap in understanding.

30 Methods: The primary outcome was putative MN as defined by ICD-10 codes occurring in the UK Biobank.
31 Univariate relative risk regression modelling was used to assess the associations between the incidence of MN
32 and related phenotypes with sociodemographic, environmental exposures, and previously described increased-
33 risk SNPs.

34 Results: 502,507 patients were included in the study of whom 100 were found to have a putative diagnosis of
35 MN; 36 at baseline and 64 during the follow-up. Prevalence at baseline and last follow-up were 72 and 199
36 cases/million respectively. At baseline, as expected, the majority of those previously diagnosed with MN had
37 proteinuria, and there was already evidence of proteinuria in patients diagnosed within the first 5 years of
38 follow-up. The highest incidence rate for MN in patients was seen in those homozygous for the high-risk alleles
39 (9.9/100,000 person-years).

40 Conclusion: It is feasible to putatively identify patients with MN in the UK Biobank and cases are still
41 accumulating. This study shows the chronicity of disease with proteinuria present years before diagnosis.
42 Genetics plays an important role in disease pathogenesis, with the at-risk group providing a potential population
43 for recall.

44

45 Keywords

46 Membranous Nephropathy; UK Biobank; Nephrotic Syndrome; Genetics

47

48

49 Introduction

50 Membranous nephropathy (MN) is among the most common causes of adult nephrotic syndrome worldwide
51 and has a significant healthcare burden, despite being a rare disease (10-12 cases per million)¹. For the majority
52 of patients, it is an autoimmune disease associated with the anti-phospholipase M-type receptor autoantibody
53 (anti-PLA₂R); a highly sensitive biomarker and seemingly pathogenic factor in its own right^{2,3}. There appears to
54 be a strong genetic contribution to the condition, with the possession of single-nucleotide polymorphisms (SNPs)
55 at *PLA2R1* and the Major Histocompatibility Complex, Class II, DQA1 (*HLA-DQA1*) conferring a dramatically
56 increased risk of developing the disease⁴⁻⁶. The most recent GWAS has also shown two further loci associated
57 with disease risk in *NKFB1* and *IRF4*⁶. However, given its rarity, understanding not only the disease pathogenesis
58 but also the risk of disease onset has been challenging. Why some patients with the genetic predisposition
59 develop a pathogenic antibody whilst others do not, has still not been elicited. Circumstantial evidence suggests
60 there may be a role for the loss of tolerance. As with other autoimmune conditions, the presence of the disease
61 associated risk SNPs are unlikely to be solely responsible for the evolution of the disease. An accompanying
62 trigger, be it environmental or pathogenic, at the correct time, is needed to initiate the immune cascade leading
63 to symptoms. The podocyte antigen peptide sequence shows similarities to a cell wall enzyme in certain
64 commonly encountered pathogens such as *Clostridia* species⁷. One study from China suggests a potential
65 environmental trigger by identifying an association between air pollution and MN compared to other
66 autoimmune glomerulopathies^{8,9}.

67 The UK Biobank holds a clinical dataset and stored deoxyribonucleic acid (DNA), serum and urine for over
68 500,000 participants, aged between 40-70 years old, recruited from across the United Kingdom from 2007-2010.
69 This age profile corresponds to the age of onset of MN with a mean of 54 years. DNA has been genotyped on a
70 genome-wide microarray with subsequent imputation.

71 Further health record data has been linked through the Hospital Episode Statistics (HES) and cancer and
72 mortality statistics¹⁰. Participant place of birth, residential area and occupation are all recorded, providing an
73 invaluable resource for the study of environmental and occupational pollution exposures¹¹⁻¹⁴. With the deep
74 phenotyping of each participant, life-long follow-up, genotyping and health record linkage, the UK Biobank
75 provides a unique and powerful tool to help understand the epidemiology of rare diseases such as MN. An initial

76 step in the use of the UK Biobank is its validation as a tool for accurately identifying patients with MN. Neither
77 International Classification of Disease tenth edition (ICD-10) nor UK Read codes (a coding system for clinical
78 terms used in the UK) have an explicit code for MN, but both coding systems have codes that will include MN
79 plus potentially several other diagnoses.

80 Here, for the first time, we have used the UK Biobank to demonstrate its feasibility and to investigate the genesis
81 of the rare kidney disease, MN.

82

83 The specific study aims were:

- 84 a) to provide a detailed description of the numbers of participants with confirmed or possible MN
85 within the UK Biobank to inform the identification of participants for further phenotyping and
86 sampling or recall for assessments
- 87 b) to determine the prevalence and incidence rates of MN in this population
- 88 c) to stratify the UK Biobank population by the genetic risk of MN
- 89 d) to assess the feasibility of linking environmental factors (infection and occupational exposure) to
90 triggering of autoimmunity in this genetically susceptible cohort

91

92

93 Methods

94 This is a cohort study in which the primary outcome was putative Membranous nephropathy (MN), defined as
95 any primary or secondary HES inpatient diagnosis of ICD-10 N02.2, N03.2, N04.2, or N05.2 occurring before the
96 UK Biobank HES data refresh in March 2019. The nominal diagnosis date was taken as the earliest such record.
97 This did not include self-reported diagnoses at the time of UK Biobank entry, or clinical diagnoses not resulting
98 in hospital admission, which are not fully available in the Biobank dataset.

99 Primary care attendance data in the UK is provided by multiple separate entities, with which UK Biobank is
100 working to allow for data linkage. At present, a subset of 228,957 UK Biobank participants had clinical
101 attendances in primary care^{11–13}. For these records putative MN was defined as the equivalent Read codes
102 version 2 (READ2) K0A22, K0A32, K021., K011, K016., K031. or READ3 codes K0A22, K021., K011., K016., K031.

103 Our descriptive study examined multiple exposures including sociodemographic characteristics and medical
104 history records recorded at the time of UK Biobank entry, as well as hospital inpatient ICD-10 diagnoses and the
105 Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4)
106 operative procedures occurring prior to the UK Biobank data as of 10th December 2019. Additional exposures
107 examined included algorithmically derived end-stage renal disease (ESRD), measures of area-level residential air
108 pollution, and Standard Occupational Classification (SOC)-2000 occupation-linked workplace airborne exposures
109 as derived from the SOC codes and the Airborne Chemical Job Exposure Matrix (ACE JEM)¹⁵. Both CKD and Renal
110 disease derived from Biobank fields f.41202 and f.41204. In addition to this, CKD defined using the ICD 10 code
111 N18 – chronic kidney disease. Renal Disease was defined using the ICD codes N0* and N1* which includes renal
112 disease but not limited to CKD. The source of each variable is provided in supplementary Table S1.

113 Given coeliac disease and type 1 diabetes mellitus classically share the same HLA class II alleles as primary MN,
114 namely HLA-DQ2.5^{29–31}, we investigated the incidence of these conditions in the UK biobank in relation to
115 identified MN cases.

116 Residential linked air pollution estimates of particulate matter air pollutants with aerodynamic diameters <10µm
117 (PM10) and <2.5µm (PM2.5 or fine PM), and gaseous air pollutions (Nitrogen Dioxide (NO₂) and Nitrogen Oxide
118 (NO)) were generated for 2010 using Land Use Regression (LUR) modelling as part of the European Study of

119 Cohorts and Air Pollution Effects (ESCAPE, <http://www.escapeproject.eu/>). Additional estimates for Nitrogen
120 Dioxide were estimated for the years 2005-2007 from EU-wide air pollution maps (resolution 100 metre x 100
121 metre) based in the LUR models, full details of the model and its performance can be found online¹⁶. All effect
122 estimates related to associations with annual estimates of each air pollution were expressed per $\mu\text{g}\text{m}^{-3}$.

123 Where descriptive statistics have been produced, the median and interquartile range (IQR) have been reported
124 for continuous measures and the proportion and percentages per category have been reported for categorical
125 variables. Where data is missing, the number of cases with missing data is reported. In reporting disease
126 incidence, the number of incident cases occurring post-UK Biobank entry has been divided by the total person-
127 years of follow-up across the disease-free UK Biobank population until March 1st 2019, accounting for individual
128 date of UK Biobank entry and recorded date of death if applicable. Baseline patients defined as those with a
129 diagnosis of MN on study entry, 'Early Incident' defined as those diagnosed within five years after study entry,
130 and 'Late Incident' defined as those patients diagnosed later than 5 years after study entry.

131 SNPs associated with MN were identified as the lead independent SNPs from 3 previous GWAS studies, referred
132 to as GWAS1-3. Allele counts identified in GWAS1⁴ were obtained from the directly genotyped Biobank dataset.
133 Allele counts from GWAS2⁵ and GWAS3⁶ were obtained from the imputed Biobank dataset. Imputed genotypes
134 were used as called regardless of any quality assessment.

135 Associations between dichotomous phenotypes and genotypes were assessed by determining the relative risk
136 (RR) associated with each genotype compared to homozygous reference alleles, and the RR per allele (additive
137 genetic model).

138 To determine univariate association between exposures of interest and MN diagnosis, generalised linear models
139 were used with non-cases as the reference category. Results were presented as relative risk ratios (RR) with
140 accompanying 95% Wald confidence intervals.

141 All statistical analyses were performed in R Version 3.5.1¹⁷. Plink v2.00 and BCFtools v1.10.2 were used to extract
142 genetic data from the UK Biobank¹⁸⁻²¹.

143

144 Results

145 MN Incidence and Prevalence

146 A total of 502,507 patients were included in the study. Based on hospital admissions, 100 participants were
147 found to have a putative diagnosis of MN as indicated by the ICD 10 codes, 36 at baseline and 64 occurring
148 during the follow-up period. At baseline, the prevalence of MN in the Biobank population was 72 cases per
149 million, with 199 cases per million at the latest follow up. There was a total of 64 incident cases, with N052
150 contributing the largest number of patients at 31. With approximately 4.98 million total person-years of follow-
151 up across the UK Biobank population, this corresponded to an incidence rate of 1.29 per 100,000 person-years,
152 with a continued rise over time as the Biobank population ages. Table 1 and figure 1.

153

154 Demographics of MN cases

155 In the MN cohort, the median age at baseline assessment was 62 years old (IQR 56 – 65), compared to a median
156 of 58 (IQR 50-63) in the non-MN group. There were 39% males in the MN cohort, compared to 54.4% males in
157 the non-MN cohort. The majority of participants in the UK Biobank with and without MN were white, with
158 similar BMI, smoking status, alcohol consumption and levels of deprivation as measured by the Townsend
159 Deprivation Index and by the Index of Multiple Deprivation. Table 2.

160

161 Clinical

162 There was a higher level of proteinuria at baseline in the MN group compared to the non-MN group, with a
163 median urinary albumin:creatinine ratio (uACR) of 3.0 mg/g (IQR 0.4-22.9) and 0.4 mg/g (IQR 0.4-0.6)
164 respectively. Renal function at baseline was also lower in the MN group with a median estimated glomerular
165 filtration rate (eGFR) 78.1ml/min/1.73m² (IQR 52.2-93.6), compared to the non-MN cohort who had a median
166 eGFR 92.8ml/min/1.73m² (IQR 82.9-100.1). Table 3.

167 For those diagnosed with MN prior to study recruitment, a majority (66%; n=21) had proteinuria at baseline with
168 a uACR of more than 3mg/g. 28% (n=9) had macro-albuminaemia with a uACR of more than 30mg/g. For those

169 diagnosed within 5 years of recruitment (early incident), there was already evidence of proteinuria at baseline,
170 with 49% (n=17) having a uACR of more than 3mg/g, and 29% (n=10) with a uACR of more than 30mg/g. In the
171 late incident group, diagnosed more than 5 years after recruitment, the majority had no evidence of proteinuria
172 at baseline with 69% (n=18) having a uACR of less than 3mg/g. For this late incident group there was proteinuria
173 noted at baseline in 31% (n=8) of patients (uACR greater than 3mg/g), and macro-albuminaemia in 15% (n=4)
174 with a uACR of more than 30mg/g. Table 3.

175 Renal function for patients diagnosed prior to recruitment and in the early incident group, as measured by eGFR,
176 was similar at baseline; median 74.3ml/min/1.73m² (IQR 46.8-86.7) in the baseline group, and median
177 76.8ml/min/1.73m² (IQR 48.8-93.8) in the early incident group. In the late incident group, the median baseline
178 eGFR was 92.9ml/min/1.73m² (IQR 76.3-95.0). Table 3.

179

180 Genetics

181 In the total population, we found that 73.4% (n=357,516) were homozygous for the low-risk *HLA-DQA1* alleles
182 (CC) and 2.4% (n=11,622) patients were homozygous for the high-risk allele (TT). For *PLA2R1*, 35.8% (n=174,588)
183 were homozygous for the high-risk alleles (AA) compared to 16.8% (n=81,861) homozygous for the low-risk GG
184 alleles. Of these, 0.8% (n=4079) were found to have both high-risk allele SNPs. Tables S2 and S3.

185 We see similar results in the UK Biobank population as in the original GWAS with respect to risk of MN diagnosis.
186 Compared to those homozygous for the low-risk *HLADQ* allele (C), being homozygous for the high-risk allele (T)
187 was associated with an 8.79 times greater risk of MN diagnosis (RR: 9.79, 95% CI: 5.36-17.85). For *PLA2R1*,
188 compared to those homozygous for the low-risk allele (G), being homozygous for the high-risk allele (A) was
189 associated with a 1.22 times greater risk of MN (RR: 2.22, 95% CI: 1.16-4.25). Considering *HLADQ* and *PLA2R1* in
190 combination, using the low-risk allele combination CCGG as the reference, the relative risk of MN for those
191 homozygous for both SNPs was 23.44 (95% CI: 7.67-71.62). There was no increased risk of MN associated with
192 being homozygous for either of the two novel lead SNPs identified in the most recent GWAS⁶. For *NFKB1*, the
193 relative risk of MN among those homozygous for the high-risk allele was 1.08 (95% CI: 0.56-2.10); and for *IRF4*,
194 the RR among those homozygous for the high-risk allele was 1.72 (95% CI: 0.62-4.75). Table 4 and Figure 2.

195 The highest incidence rate of MN was seen in those homozygous for the high-risk *HLA-DQA1* allele (TT) and high-
196 risk *PLA2R1* allele (AA), with an incidence rate of 9.9 cases per 100,000 person-years. The lowest-risk group
197 (CCGG) had an incidence rate of 0.5 cases per 100,000 person-years. Table 5.

198 Subgroup analysis comparing the cohorts homozygous for both the high-risk alleles for *HLA-DQA1* and *PLA2R1*
199 (TT and AA respectively) with those not homozygous for both show a similar proportion of diabetes, both self-
200 reported and through HES linkage. In the high-risk group, 2.8% of individuals self-reported having coeliac
201 disease, and 3.2% were identified as having coeliac disease through HES linkage, this is compared to 0.4% and
202 0.5% respectively, in the low-risk group. Table S4.

203 At baseline, there was no difference in eGFR in patients homozygous for the high-risk *HLA-DQA1* and *PLA2R1*
204 alleles (TTAA) compared to those not. For uACR, the high-risk group showed weak association with a higher
205 degree of proteinuria over 30 mg/g; 0.71% among those homozygous for TTAA, compared to 0.47% in those not
206 homozygous for the high-risk alleles (not TTAA). Table S4.

207

208 Using patients with baseline proteinuria data, and homozygous for the low-risk allele for *HLA-DQA1* as reference,
209 there was a weak negative association with mild or macro-albuminaemia for those homozygous for the high-
210 risk alleles (TT); (RR: 0.94, 95% CI: 0.86-1.02). Patients homozygous for the high-risk *PLA2R1* allele (AA) were
211 slightly more likely to have mild proteinuria (RR: 1.05, 95% CI: 1.01-1.08) and heavy proteinuria (RR: 1.11, 95%
212 CI: 0.99-1.26), compared to the low-risk allele group (CC). Table S5.

213

214 Pollution and Work-Related Environmental Exposures

215 Univariate comparisons indicated no significant associations between increased environmental exposure to
216 Nitrogen Dioxide, Nitrogen Oxides, or Particulate Matter and risk of MN diagnosis. Likewise, no significant
217 associations were found between work-related environmental exposures and risk of MN diagnosis, though
218 comparisons were subject to small sample sizes among those exposed with MN. Tables 6 and S6.

219 Primary care data

220 Data from primary care records was available for a subset of 228,957 (45.6%) participants. Of these, there were
221 38 patients identified as putative MN cases using the previously defined READ codes. Using hospital admissions
222 data, 41 patients in this subset were identified as having MN using the previously defined ICD codes. Of all
223 identified patients with MN, 19 were identified in both sources, 19 only in primary care and 22 only through
224 hospital admissions. For those patients identified in both sources, the majority were coded in both databases at
225 the same time, but there were a number of patients with diagnoses in the primary care database for whom
226 diagnosis was coded years in advance of hospital admission. The age distribution at first hospital admission was
227 similar among patients included and not included in the primary care database. However, some of the primary
228 care cases not identified by hospital admissions were diagnosed at a younger age. Supplementary figure S7.

229 Discussion

230 This is the first study to examine the occurrence and determinants of MN within the UK Biobank cohort. We
231 have shown that putative MN cases can be identified at entry to the UK Biobank study as well as throughout
232 follow-up. The incidence rate calculated here of 1.29 diagnoses per 100,000 person-years is similar to previously
233 reported rates in other studies^{1,8,9,22-24}. Most previous studies reporting incidence rates for MN are based on
234 retrospective data from biopsies – a possibly unrepresentative cohort given the inherent suspicion of an
235 underlying kidney disease. In contrast, the UK Biobank cohort is ostensibly a population-based sample (see Fry
236 *et al* for consideration of the sample representativeness¹⁴), with this study being the first to evaluate MN
237 occurrence in such a population.

238 At present MN remains a biopsy-diagnosed condition requiring specialist input, usually in a tertiary referral
239 centre in the UK. The coding for MN in primary care records is therefore generally based on correspondence
240 from a tertiary care centre, meaning patients assigned codes for MN are highly likely to have the condition
241 (unpublished work). However, there is no unifying code for MN in either ICD-10 or READ codes, and those that
242 are available include adjunctive diagnoses. This raises the possibility that patients with MN could be missed, as
243 they have been coded with more generic descriptions of the condition such as nephrotic syndrome. A number
244 of patients identified from primary care data were diagnosed prior to the initiation of HES and who do not,
245 therefore, appear in the hospital admissions database at all, or who appear years later. It may be that some of
246 these patients were already in remission before the commencement of HES data, and therefore were never
247 captured. At present, the available HES data also does not capture outpatient episodes, meaning patients
248 already diagnosed prior to the commencement of the database, will not be identified as they are only seen in
249 the outpatient clinic setting and not as an inpatient. Patients in remission could appear in the HES database
250 years after identification in the General Practitioner (GP) database, owing to a relapse necessitating admission
251 to a specialist nephrology centre. An ongoing limitation with data linkage in the UK Biobank is the incomplete
252 coverage of both primary care data and HES, although this is being continuously addressed and updated.

253 MN is a disease of middle to late age, with the median age at baseline here of 62 years old^{25,26}. We found a
254 female predominance for MN in the UK Biobank, which is in-keeping with autoimmune disease in general
255 although not specifically in MN²⁷. A number of studies in the past have shown the opposite is true with MN,

256 however, though this prior work has been inconsistent, emblematic of the difficulty of epidemiological studies
257 in examining this rare disease¹.

258 As expected, there was a higher degree of proteinuria and lower eGFR at baseline in our study in patients with
259 MN compared to the non-MN cohort. Interestingly, those patients who had no diagnosis of MN at baseline but
260 who went on to be diagnosed within 5 years already had evidence of subclinical biochemical abnormalities
261 suggestive of MN. Almost half of these early incident patients had some degree of proteinuria and over a third
262 had an eGFR of less than 60ml/min/1.73m². These findings are similar to other recent studies²⁸, and are
263 indicative of the chronicity and slowly progressive nature of the disease, with patients experiencing ongoing
264 pathogenic autoantibody production and glomerular damage years before it becomes clinically apparent.
265 Identification of this prodromal cohort in the UK Biobank offers a unique opportunity to confirm the early role
266 of anti-PLA₂R in pathogenesis up to 5 years prior to clinical diagnosis of MN using the sera stored at study entry.
267 It also allows testing of the hypothesis that infection could be the environmental trigger for MN by interrogation
268 of the IgG antibody proteome library in early serum samples first positive for anti-PLA₂R, in comparison to
269 age/gender-matched controls. It may be possible to identify a unique IgG phenotype to infectious agents
270 coincident with the onset of anti-PLA₂R autoantibodies.

271 Currently 80% of autoimmune MN patients present with nephrotic syndrome without any prior indication of an
272 underlying kidney disease, but with proteinuria and autoantibody production that may have been active for a
273 variable period before this. Although the exact cause is still unknown, knowledge of the disease pathogenesis
274 has increased markedly since the discovery of the anti-PLA₂R autoantibody. There is undoubtedly a strong
275 genetic component to autoimmune MN, with multiple GWAS initially identifying two genes, *HLA-DQA1* and
276 *PLA2R1* in Europeans, and more recently *NFKB1* and *IRF4*, that all account for susceptibility to MN. Possession
277 of homozygous pathological alleles of *HLA-DQA1* and *PLA2R1* raises the odds ratio from 1 to 78 for having the
278 disease⁴. What is not known, is how likely it is for a patient to develop MN in the presence of these high-risk
279 alleles. What is the lifetime risk of developing MN conferred by the high-risk alleles? Certainly, in our study, the
280 relative risk of MN is significantly higher in patients homozygous for the *HLA-DQA1* and *PLA2R1* compared to
281 those without any of the risk alleles (RR: 23.4, 95% CI: 7.7-71.6). Homozygosity of risk alleles in *HLA-DQA1* and
282 *PLA2R1* resulted in a higher incidence of MN (9.9 cases per 100,000 person-years) and a higher degree of macro-
283 albuminaemia. This suggests not only a higher incidence but also a more severe phenotype in keeping with

284 previous work showing an association of individuals with the *HLA-DQA1* risk alleles having higher anti-PLA2R
285 antibodies²⁶. There was a low penetrance with only 0.20% of patients homozygous for the high-risk alleles
286 having, or developing MN, during the study follow-up, but as UK Biobank is a lifetime epidemiology study, the
287 risk of developing MN will become evident. Given the chronicity of MN disease and its diagnosis late in life for
288 most patients, this is a group of patients in whom active follow-up would be essential in order to determine the
289 strength of genetics on the development of the disease.

290 We found no evidence for an increase in MN diagnosis in relation to particulate exposure or occupational
291 exposures to heavy metals and hydrocarbons. This may be related to the much lower levels of exposure among
292 patients in the UK compared to China, where this association was first described in biopsy patients^{8,9}. In our
293 cohort, the median level of exposure over the study period was 10.0 $\mu\text{g}\text{m}^{-3}$ for particulate matter of less than
294 2.5 μm , compared to a mean of 55.6 $\mu\text{g}\text{m}^{-3}$ (range 8.1 to 110.5) in China. Limitations to this comparison include
295 the small numbers of exposed cases, lack of data on previous exposures, and the study population being
296 generally more educated and from a higher socioeconomic background compared to the general population,
297 and therefore potentially less likely to be exposed to higher pollution levels – all influencing the statistical power
298 of environmental comparisons and our ability to detect plausible magnitude associations. A significantly larger
299 study population would be required to investigate this further at lower particulate matter levels, and at present
300 would be outside the remit of the UK Biobank.

301

302

303 Conclusion

304 Here we have shown for the first time that it is feasible to putatively identify patients with MN in the UK Biobank,
305 both at study entry and over time, allowing for the use of this powerful resource to study initiation of a rare
306 autoimmune disease in greater depth than previously possible, however definitive diagnosis would require
307 participant or stored sample access. This study provides further evidence for the chronicity of disease with
308 proteinuria present years prior to diagnosis in a number of patients. Genetics also plays an important role in
309 the development of the disease although with low penetrance. Patients with the high-risk alleles provide an
310 invaluable study population for prospective investigation of the disease process, this is particularly pertinent
311 given the potential for missed cases in the database. This at-risk group would be an important sample for recall
312 to interrogate further. Despite the low numbers of MN patients identified, this is the most comprehensive study
313 of MN in a defined population to date. Importantly it also provides a baseline for further work to understand
314 the pathogenesis of the disease as follow-up progresses.

315

316

317

318 Author Contributions

319 PB – project conception

320 PB, SR, DAK and PH – project protocol development

321 KB, SR and MG – data analysis

322 MLD, CV, HS, SG, SR - Genetic Analysis

323 PH – draft manuscript preparation

324 All authors – manuscript review

325

326

327 Acknowledgements

328 This was an approved study (I.D. 1618) by UK BioBank (<http://ukbiobank.org>). We acknowledge funding from

329 Kidney Research UK (KRUK) for the Stoneygate Foundation Grant JFS_IN_003_20160914

330 MLD was supported by the KRESCENT post-doctoral fellowship from the Kidney Foundation of Canada

331

332

333 Disclosures

334 None

335

336

337

338

339

340

341

342 References

- 343 1. McGrogan A, Franssen CFM, Vries CS de. The incidence of primary glomerulonephritis worldwide: a systematic review of
344 the literature. *Nephrol Dial Transpl.* 2011;26(2):414-430. doi:10.1093/ndt/gfq665
- 345 2. Beck L, Bonegio R, Lambeau G, et al. M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous
346 Nephropathy. *N Engl J Med.* 2009;361(1):11-21. doi:10.1056/nejmoa0810457
- 347 3. Logt AE van de, Fresquet M, Wetzels JF, Brenchley P. The anti-PLA2R antibody in membranous nephropathy: what we
348 know and what remains a decade after its discovery. *Kidney Int.* 2020;96(6):1292-1302. doi:10.1016/j.kint.2019.07.014
- 349 4. Stanescu H, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy.
350 *N Engl J Med.* 2011;364(7):616-626. doi:10.1056/nejmoa1009742
- 351 5. Sekula P, Li Y, Stanescu HC, et al. Genetic risk variants for membranous nephropathy: extension of and association with
352 other chronic kidney disease aetiologies. *Nephrol Dial Transpl.* 2017;32(2):325-332. doi:10.1093/ndt/gfw001
- 353 6. Xie J, Liu L, Mladkova N, et al. The genetic architecture of membranous nephropathy and its potential to improve non-
354 invasive diagnosis. *Nat Commun.* 2020;11(1):1600. doi:10.1038/s41467-020-15383-w
- 355 7. Fresquet M, Jowitt TA, Gummadova J, et al. Identification of a Major Epitope Recognized by PLA2R Autoantibodies in
356 Primary Membranous Nephropathy. *J Am Soc Nephrol.* 2014;26(2):302-313. doi:10.1681/asn.2014050502
- 357 8. Li J, Cui Z, Long J, et al. Primary glomerular nephropathy among hospitalized patients in a national database in China.
358 *Nephrol Dial Transpl.* Published online 2018. doi:10.1093/ndt/gfy022
- 359 9. Xu X, Wang G, Chen N, et al. Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in
360 China. *J Am Soc Nephrol.* 2016;27(12):3739-3746. doi:10.1681/asn.2016010093
- 361 10. (HSCIC) H and SCIC. Hospital Episode Statistics. Accessed January 15, 2021. [https://digital.nhs.uk/data-and-
362 information/data-tools-and-services/data-services/hospital-episode-statistics#further-information](https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics#further-information)
- 363 11. Elliott P, Peakman TC, Biobank U. The UK Biobank sample handling and storage protocol for the collection, processing
364 and archiving of human blood and urine. *Int J Epidemiol.* 2008;37(2):234-244. doi:10.1093/ije/dym276
- 365 12. Ollier W, Sprosen T, Peakman T. UK Biobank: from concept to reality. *Pharmacogenomics.* 2005;6(6):639-646.
366 doi:10.2217/14622416.6.6.639
- 367 13. Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of
368 Complex Diseases of Middle and Old Age. *Plos Med.* 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 369 14. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank
370 Participants With Those of the General Population. *Am J Epidemiol.* 2017;186(9):1026-1034. doi:10.1093/aje/kwx246
- 371 15. Sadhra SS, Kurmi OP, Chambers H, Lam KBH, Fishwick D, Group TOCR. Development of an occupational airborne chemical
372 exposure matrix. *Occup Med-c.* 2016;66(5):358-364. doi:10.1093/occmed/kqw027
- 373 16. Vienneau D, Hoogh K de, Bechle MJ, et al. Western European Land Use Regression Incorporating Satellite- and Ground-
374 Based Measurements of NO₂ and PM₁₀. *Environ Sci Technol.* 2013;47(23):13555-13564. doi:10.1021/es403089q
- 375 17. (2019) RCT. R: A Language and Environment for Statistical Computing.; 2019. <https://www.R-project.org/>
- 376 18. Purcell S, Chang C. PLINK 2.0. www.cog-genomics.org/plink/2.0/
- 377 19. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger
378 and richer datasets. *Gigascience.* 2015;4(1):7. doi:10.1186/s13742-015-0047-8

- 379 20. Danecek P, Bonfield JK, Liddle J, et al. Twelve years of SAMtools and BCFtools. *Gigascience*. 2021;10(2):giab008.
380 doi:10.1093/gigascience/giab008
- 381 21. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter
382 estimation from sequencing data. *Bioinformatics*. 2011;27(21):2987-2993. doi:10.1093/bioinformatics/btr509
- 383 22. Hanks JB, Mullan RN, O'Rourke DM, McNamee PT, Maxwell AP, Courtney AE. The changing pattern of adult primary
384 glomerular disease. *Nephrology Dialysis Transplantation*. 2009;24(10):3050-3054. doi:10.1093/ndt/gfp254
- 385 23. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-
386 year renal biopsy study. *Clin J Am Soc Nephrol*. 2006;1(3):483-487. doi:10.2215/cjn.00710805
- 387 24. Tang L, Yao J, Kong X, et al. Increasing prevalence of membranous nephropathy in patients with primary glomerular
388 diseases: A cross-sectional study in China. *Nephrology*. 2017;22(2):168-173. doi:10.1111/nep.12739
- 389 25. Floege J, Amann K. Primary glomerulonephritides. *The Lancet*. 2016;0(0). doi:10.1016/s0140-6736(16)00272-5
- 390 26. Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome
391 in a prevalent population of patients with idiopathic membranous nephropathy. *Kidney Int*. 2013;83(5):940-948.
392 doi:10.1038/ki.2012.486
- 393 27. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and Estimated Population Burden of Selected Autoimmune
394 Diseases in the United States. *Clin Immunol Immunop*. 1997;84(3):223-243. doi:10.1006/clin.1997.4412
- 395 28. Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R Autoantibodies before the Diagnosis of Membranous
396 Nephropathy. *J Am Soc Nephrol*. 2019;31(1):208-217. doi:10.1681/asn.2019050538
- 397 29. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. *Curr Diab Rep*. 2011 Dec;11(6):533-
398 42. doi: 10.1007/s11892-011-0223-x. PMID: 21912932; PMCID: PMC3233362.
- 399 30. Sollid, L. M. et al. Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. *J*
400 *Exp Medicine* 169, 345–350 (1989).
- 401 31. Lundin, K. E. et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal
402 mucosa of celiac disease patients. *J Exp Medicine* 178, 187–196 (1993).
- 403

404 Supplementary Material Table of Contents (PDF)

405

406 Table S1 Biobank fields and variable definitions

407 Table S2 Allele counts at the lead SNPs from GWAS1⁴, GWAS2⁵, and GWAS3⁶ in all UK Biobank
408 participants using the imputed UK Biobank datasets

409 Table S3 Counts of genotype combinations at the lead SNPs from GWAS1⁴ and GWAS2⁵ in all UK
410 Biobank participants using both the imputed UK Biobank datasets

411 Table S4 Phenotype per combined genotype group at HLADQA1 (rs2187668, test allele T) and PLA2R1
412 (rs4664308, test allele A) from GWAS1⁴ in all UK Biobank participants using the directly
413 genotyped UK Biobank dataset

414 Table S5 Phenotype and genotype by degree of proteinuria for all UK Biobank participants, with
415 genotypes obtained from the imputed UK Biobank dataset at the lead SNPs from GWAS1⁴
416 and GWAS2⁵.

417 Table S6 Environmental exposures – work-related

418

419 Figure S7 A) Time difference from GP diagnosis to HES diagnosis where the case was identified in both
420 sources.

421 B) Age distributions of the cases identified in the two sources

422 C) Date of diagnosis of the cases identified in the two sources

423

424 Figure Legends

425

426 **Figure 1:** Monthly cumulative incidence of MN. A) Cases identified each calendar month B) Kaplan-Meier
427 estimate by age with 95%CI.

428 **Figure 2:** Genetic Risk of MN by PLA2R1 and HLADQ. Based on directly called SNPs determined in GWAS1⁴

429

430

ICD10	Description	Cases Detected		Prevalence per million		Incident Cases	Incidence Rate (per 100,000 person-years)
		Baseline	Last follow up	Baseline	Last follow up		
N022	Recurrent and persistent haematuria with diffuse membranous glomerulonephritis	5	35	10	70	30	0.60
N032	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	4	12	8	24	8	0.16
N042	Nephrotic syndrome with diffuse membranous glomerulonephritis	4	27	8	54	23	0.46
N052	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	25	56	50	111	31	0.62
Total	Putative Membranous Nephropathy	36	100	72	199	64	1.29

Table 1 – incidence and prevalence

Characteristics		No MN	MN
<i>N</i>		502407	100
Age at baseline assessment	Median [IQR]	58 [50-63]	62 [56-65]
Age at last follow-up (death or end of HES data)	Median [IQR]	68 [60-73]	70 (65-74)
Sex	Male	273345/502407 (54.4%)	39/100 (39%)
	Female	229062/502407 (45.6%)	61/100 (61%)
Ethnicity	White	472608/501509 (94.2%)	90/100 (90%)
	Asian	9877/501509 (2.0%)	5/100 (5%)
	Black	8059/501509 (1.6%)	2/100 (2%)
	Mixed/Other	9087/501509 (1.8%)	3/100 (3%)
	Not Known	1878/501509 (0.4%)	0/100 (0%)
BMI	Median [IQR]	26.7 [24.1-29.9]	27.5 [24.5-30.7]
	NA	3104	1
Smoking Status	Prefer not to answer	2057/501516 (0.4%)	0/100 (0%)
	Never	273472/501516 (54.5%)	50/100 (50%)
	Previous	173018/501516 (34.5%)	40/100 (40%)
	Current	52969/501516 (10.6%)	10/100 (10%)
Alcohol Consumption	Prefer not to answer	756/501510 (0.2%)	0/100 (0%)
	Never	22377/501510 (4.5%)	8/100 (8%)
	Previous	18102/501510 (3.6%)	2/100 (2%)
	Current	460275/501510 (91.8%)	90/100 (90%)
Alcohol Consumption Frequency	Prefer not to answer	604/501510 (0.1%)	0/100 (0%)
	Daily or almost daily	101751/501510 (20.3%)	18/100 (18%)
	Three or four times a week	115422/501510 (23.0%)	18/100 (18%)
	Once or twice a week	129265/501510 (25.8%)	27/100 (27%)
	One to three times a month	55848/501510 (11.1%)	7/100 (7%)
	Special occasions	57989/501510 (11.6%)	20/100 (20%)
	Never	40631/501510 (8.1%)	10/100 (10%)
Townsend Deprivation Index	Median [IQR]	-2.1 [-3.6-0.6]	-1.9 [-3.9-0.5]
	NA	623	0
Index of Multiple Deprivation	Median [IQR]	12.8 [7.1-23.3]	16.5 [8.4-27.6]
	NA	12737	0

Table 2 – Demographics for the UK Biobank population

	No MN	MN				
		Any	Baseline	Early Incident	Late Incident	
	502,407	100	36	36	28	
Self-reported Renal Failure	872/502407 (0.2%)	12/100 (12%)	8/36 (22%)	4/36 (11%)	0/28 (0%)	
HES CKD	9033/502407 (1.8%)	49/100 (49%)	16/36 (44.%)	20/36 (56%)	13/28 (46%)	
HES Renal Disease	21931/502407 (4.4%)	100/100 (100%)	36/36 (100%)	36/36 (100%)	28/28 (100%)	
Algorithmically derived ESRD	1168/502407 (0.2%)	23/100 (23%)	8/36 (22%)	11/36 (31%)	4/28 (14%)	
uACR at baseline (mg/g)	<3	458536/484201 (94.7%)	47/93 (50.5%)	11/32 (34%)	18/35 (51%)	18/26 (69%)
	3-30	23405/484201 (4.8%)	23/93 (25%)	12/32 (38%)	7/35 (20%)	4/26 (15%)
	30-250	2128/484201 (0.4%)	15/93 (16%)	7/32 (22%)	4/35 (11%)	4/26 (15%)
	>250	132/484201 (0.03%)	8/93 (8.6%)	2/32 (6%)	6/35 (17%)	0/26 (0%)
	Median (IQR)	0.4 (0.4-0.6)	3.0 (0.4-22.9)	7.2 (2.6-31.2)	1.9 (0.4-99.2)	0.6 (0.4-8.8)
	Unknown	18206	7	4	1	2
eGFR at baseline (ml/min/1.73m ²)	≥90	277341/468781 (59.2%)	32/89 (36%)	6/31 (19.4%)	11/33 (33%)	15/25 (60.0%)
	60-90	180729/468781 (38.6%)	31/89 (35%)	13/31 (42%)	10/33 (30%)	8/25 (32%)
	15-60	10571/468781 (2.3%)	24/89 (27%)	11/31 (36%)	11/33 (33%)	2/25 (8%)
	<15	140/468781 (0.03%)	2/89 (2%)	1/31 (3%)	1/33 (3.0%)	0/25 (0%)
	Median (IQR)	92.8 (82.9-100.1)	78.1 (52.2-93.6)	74.3 (46.8-86.7)	76.8 (48.8-93.8)	92.9 (76.3-95.0)
	Unknown	33626	11	5	3	3
Self-reported Diabetes	25468/502407 (5.1%)	12/100 (12%)	5/36 (14%)	5/36 (14%)	2/28 (7.%)	
HES Diabetes	31266/502407 (6.2%)	17/100 (17%)	8/36 (22%)	6/36 (17%)	3/28 (11%)	
Self-reported Coeliac Disease	2049/502407 (0.4%)	0/100 (0%)	0/36 (0.)	0/36 (0%)	0/28 (0%)	
HES Coeliac Disease	2481/502407 (0.5%)	1/100 (1%)	1/36 (3%)	0/36 (0%)	0/28 (0%)	
Self-reported Renal Biopsy	129/502407 (0.03%)	3/100 (3%)	3/36 (8%)	0/36 (0%)	0/28 (0%)	
OPCS Renal Biopsy	288/413517 (0.07%)	6/100 (6%)	3/36 (8%)	2/36 (6%)	1/28 (4%)	

Table 3 – Phenotype per group. Relationship between baseline cases, all incident cases, and incident cases ≤5 years from baseline. MN = Membranous Nephropathy, HES = Hospital Episode Statistics, CKD = Chronic Kidney Disease, ESRD = End-Stage Renal Disease, ACR = urinary albumin:creatinine ratio, eGFR = estimated Glomerular Filtration Rate, IQR = Inter-Quartile Range, SD = Standard Deviation, OPCS = OPCS Classification of Interventions and Procedures. See supplementary material table 1 for biobank variable codes and sources. eGFR calculated at baseline, algorithmically derived ESRD assessed throughout follow up period.

			MN	RR (95% CI)	GWAS OR
GWAS1 ⁴	HLADQA1 rs2187668	CC	44/357516 (0.01%)	1	
		CT	39/118070 (0.03%)	2.68 (1.74-4.13)	
		TT	14/11622 (0.12%)	9.79 (5.36-17.85)	
		OR Per allele		3.11 (2.31-4.18)	4.32 (3.73-5.01)
	PLA2R1 rs4664308	GG	11/81861 (0.01%)	1	
		AG	34/230759 (0.02%)	1.10 (0.56-2.16)	
		AA	52/174588 (0.03%)	2.22 (1.16-4.25)	
		OR Per allele		1.66 (1.22-2.26)	2.28 (1.9--2.64)
GWAS2 ⁵	HLADQA1 rs9272729	GG	44/351417 (0.01%)	1	
		AG	41/117731 (0.04%)	2.78 (1.82-4.26)	
		AA	12/10747 (0.11%)	8.92 (4.71-16.88)	
		OR Per allele		2.99 (2.17-4.11)	6.86 (4.55-10.3)
	PLA2R1 rs17830558	GG	22/138318 (0.02%)	1	
		TG	40/228842 (0.02%)	1.10 (0.65-1.85)	
		TT	33/105620 (0.03%)	1.96 (1.15-3.37)	
		OR Per allele		1.44 (1.08-1.90)	1.63 (1.23-2.15)
GWAS3 ⁶	HLADRB1/DQ A1 rs9271573	CC	24/170192 (0.01%)	1	
		AC	41/234411 (0.02%)	1.24 (0.75-2.05)	
		AA	32/82375 (0.04%)	2.75 (1.62-4.68)	
		OR per allele		1.70 (1.28-2.25)	2.41 (2.26-2.57)
	PLA2R1 rs17831251	TT	11/80771 (0.014%)	1	
		CT	33/227843 (0.01%)	1.06 (0.54-2.10)	
		CC	51/172495 (0.03%)	2.17 (1.13-4.16)	
		OR per allele		1.67 (1.22-2.28)	2.25 (2.09-2.42)
	NFKB1 rs230540	CC	11/59492 (0.02%)	1	
		CT	43/216576 (0.02%)	1.07 (0.55-2.08)	
		TT	41/205265 (0.02%)	1.08 (0.56-2.10)	
		OR per allele		0.97 (0.72-1.31)	1.25 (1.17-1.33)
IRF4 rs9405192	AA	4/33043 (0.01%)	1		
	GA	39/182247 (0.02%)	1.77 (0.63-4.95)		
	GG	54/259096 (0.02%)	1.72 (0.62-4.75)		
	OR per allele		0.90 (0.65-1.25)	1.29 (1.21-1.37)	
GWAS1 ⁴ SNP Combinations	HLADQA1 rs2187668 PLA2R1 rs4664308	CCGG	5/59756 (0.01%)	1	
		CCAG	17/168473 (0.01%)	1.21 (0.44-3.27)	
		CCAA	22/129287 (0.02%)	2.03 (0.77-5.37)	
		CTGG	4/20131 (0.02%)	2.37 (0.64-8.84)	
		CTAG	13/56717 (0.02%)	2.74 (0.98-7.68)	
		CTAA	22/41222 (0.05%)	6.38 (2.42-16.84)	
		TTAG	4/5569 (0.07%)	8.58 (2.31-31.96)	
		TTGG	2/1974 (0.10%)	12.11 (2.35-62.37)	
GWAS1 ⁴ Risk Groups	Low Risk	CCGG	5/59756 (0.01%)	1	
	Medium Risk	All else	84/423373 (0.02%)	2.37 (0.96-5.85)	
	High Risk	TTAA	8/4079 (0.20%)	23.44 (7.67-71.62)	
GWAS1 ⁴ PLA2R1 Groups	No PLA2R1 allele	CCGG, CTGG, TTGG	11/81861 (0.01%)	1	
	PLA2R1 Allele	All Else	86/405347 (0.02%)	1.58 (0.84-2.96)	



Table 4 – Genetic risk analysis in the membranous nephropathy cohort using the lead SNPs from GWAS1⁴, GWAS2⁵ and GWAS3⁶ from the imputed UK Biobank dataset. *MN* - Membranous Nephropathy, *RR* - Relative Risk, *CI* - Confidence Interval, *GWAS* - Genome-wide Association Study, *OR* - Odds Ratio, *SNP* - Single Nucleotide Polymorphism

Genotype Groups		MN Prevalence		Incident Cases	Total Follow-up (in 100,000 years)	Incidence Rate (per 100,000 years)
		Baseline	Last follow up			
GWAS1 HLADQA1 and PLA2R1 SNP Combinations	CCGG	2	5	3	5.92	0.5
	CTGG	1	4	3	2.00	1.5
	TTGG	0	2	2	2.00	10.2
	CCAG	5	17	12	16.68	0.7
	CTAG	5	13	8	5.62	1.4
	TTAG	1	4	3	0.55	5.5
	CCAA	4	22	18	12.77	1.4
	CTAA	13	22	9	4.08	2.2
	TTAA	4	8	4	0.40	9.9
	Unknown HLADQ or PLA2R1	1	3	2	1.60	1.3
Risk Groups	Low Risk (CCGG)	2	5	3	5.92	0.5
	Medium Risk (All Else)	29	84	55	41.88	1.3
	High Risk (TTAA)	4	8	4	0.40	9.9
PLA2R1 Allele Groups	No PLA2R1 Allele (CCGG, CTGG, TTGG)	3	11	8	8.11	1.0
	PLA2R1 Allele (All Else)	32	86	54	40.10	1.3

Table 5 - Prevalence and incidence measures for: those in high-risk and low-risk groups; those with a PLA2R1 allele and without a PLA2R1 allele

Pollution Metric		No MN	MN	RR (95% CI)
		Median [IQR]	Median [IQR]	
Nitrogen Dioxide	2005	28.4 [23.1-34.7]	28.9 [24.2-36.6]	1.01 (0.99-1.03)
	2006	27.9 [22.8-33.3]	28.4 [23.7-35.2]	1.01 (0.99-1.03)
	2007	28.9 [23.6-35.0]	30.3 [24.5-36.7]	1.01 (0.99-1.03)
	2010	26.2 [21.5-31.3]	26.4 [21.8-30.9]	1.01 (0.98-1.03)
Nitrogen Oxides	2010	42.4 [34.4-50.8]	42.9 [34.6-51.2]	1.00 (0.99-1.01)
Particulate Matter	<2.5um	9.9 [9.3-10.6]	10.0 [9.5-10.5]	1.02 (0.84-1.23)
	<10um	16.0 [15.2-17.0]	16.1 [15.4-16.8]	0.98 (0.88-1.09)
Distance to main road (per 100 metres)		377.4 [166.9-751.9]	378.8 [228.6-711.8]	0.98 [0.95-1.02]

Table 6 - Associations with environmental exposures presented in $\mu\text{g}\text{m}^{-3}$. pollution exposure: Identified MN cases versus controls with no diagnosed MN

A**B****Figure 1**




Figure 2